| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CCR Focus |
Authors' Affiliations: 1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine; 2 Varmus Laboratory, Program in Cancer Biology and Genetics; and 3 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York
Requests for reprints: William Pao, Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Box 125, 1275 York Avenue, New York, NY 10021. Phone: 212-639-2761; Fax: 212-794-4357; E-mail: paow{at}mskcc.org.
In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with non–small cell lung cancer. Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non–small cell lung cancer. Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions.
This article has been cited by other articles:
|
|
 |
|
  D. B. Costa, K.-S. H. Nguyen, B. C. Cho, L. V. Sequist, D. M. Jackman, G. J. Riely, B. Y. Yeap, B. Halmos, J. H. Kim, P. A. Janne, et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib Clin. Cancer Res., November 1, 2008; 14(21): 7060 - 7067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Kruse, M. Bantscheff, G. Drewes, and C. Hopf Chemical and Pathway Proteomics: Powerful Tools for Oncology Drug Discovery and Personalized Health Care Mol. Cell. Proteomics, October 1, 2008; 7(10): 1887 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Gazdar and J. D. Minna Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops Cancer Prevention Research, August 1, 2008; 1(3): 156 - 160. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Braiteh, R. Kurzrock, and F. M. Johnson Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib J. Clin. Oncol., July 10, 2008; 26(20): 3460 - 3462. [Full Text] [PDF]
|
|
|
|
|
|
R. Iwakawa, T. Kohno, Y. Anami, M. Noguchi, K. Suzuki, Y. Matsuno, K. Mishima, R. Nishikawa, F. Tashiro, and J. Yokota Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma Clin. Cancer Res., June 15, 2008; 14(12): 3746 - 3753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, E. T. Petri, B. Halmos, and T. J. Boggon Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1742 - 1751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yang, M. Wislez, N. Fujimoto, L. Prudkin, J. G. Izzo, F. Uno, L. Ji, A. E. Hanna, R. R. Langley, D. Liu, et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras Mol. Cancer Ther., April 1, 2008; 7(4): 952 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, et al. Signaling networks assembled by oncogenic EGFR and c-Met PNAS, January 15, 2008; 105(2): 692 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bean, C. Brennan, J.-Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib PNAS, December 26, 2007; 104(52): 20932 - 20937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu Cancer Res., July 15, 2007; 67(14): 6825 - 6843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Johnson, V. W. Rusch, and A. T. Turrisi Scalpels, Beams, Drugs, and Dreams: Challenges of Stage IIIA-N2 Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 21, 2007; 99(6): 415 - 418. [Full Text] [PDF]
|
|
|
|
|
|
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
